

## Scandinavian ChemoTech - Strong sales in the quarter

Redeye provides an update on Scandinavian ChemoTech following the Q2 2024 report. We view the performance from the company to be in line with forecasts, with the deviations partly a result of one-offs. We mostly maintain our estimates and make a miniscule adjustment to our valuation range.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

## **Attachments**

Scandinavian ChemoTech - Strong sales in the quarter